A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs

Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high me...

Descripción completa

Detalles Bibliográficos
Autores principales: Igase, Masaya, Nemoto, Yuki, Itamoto, Kazuhito, Tani, Kenji, Nakaichi, Munekazu, Sakurai, Masashi, Sakai, Yusuke, Noguchi, Shunsuke, Kato, Masahiro, Tsukui, Toshihiro, Mizuno, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591904/
https://www.ncbi.nlm.nih.gov/pubmed/33110170
http://dx.doi.org/10.1038/s41598-020-75533-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591904/
https://www.ncbi.nlm.nih.gov/pubmed/33110170
http://dx.doi.org/10.1038/s41598-020-75533-4

Ejemplares similares